Search for Biological Markers of Orosensory Perception of Fatty Acids in Healthy Subjects and Possible Modifications in Patients With Type 2 Diabetes and in Obese Non-diabetic Patients.

NCT ID: NCT02028975

Last Updated: 2014-01-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Animal studies have shown that stimulation of the lingual lipid-receptor, CD 36, is accompanied by the rapid secretion of hormones in the digestive tract (incretines). We aim to determine in healthy humans whether the orosensory perception of fatty acids is followed by a modification in plasma levels of digestive tract hormones (cholecystokinin, GIP, GLP-1, secretin, pancreatic peptide, peptide YY, insulin) and metabolic markers from adipose tissue (leptin, ghrelin, adiponectin).

We also aim to determine whether the hormonal response induced by orosensory stimulation by lipids is modified:

* in patients with type 2 diabetes
* in obese non-diabetic patients We expect to show an increase in biological markers biological, and more particularly in certain digestive hormones such as Pancreatic polypeptide, GIP, GLP-1…after stimulation of the lingual lipid receptor, CD36. We will also determine whether or not this response is modified in patients with type 2 diabetes and in obese non-diabetic patients.

We also wish to measure the subjects' gustatory detection threshold for a fatty acid (linoleic acid), and to determine whether there is a relationship between the orosensory perception threshold for linoleic acid and the physiological status of the subjects. In order to achieve this, the thresholds for healthy subjects will be compared with thresholds for obese and diabetic subjects. Expected results: the threshold of detection for linoleic acid in healthy subjects will be lower than that in obese or diabetic patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes or Obesity Without Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with type 2 diabetes

Group Type OTHER

Measure the threshold of detection for linoleic acid

Intervention Type OTHER

Oral stimulation tests

Intervention Type OTHER

Venous blood samples

Intervention Type OTHER

Samples for genetic studies (ancillary study)

Intervention Type OTHER

Obese patients without diabetes

Group Type OTHER

Measure the threshold of detection for linoleic acid

Intervention Type OTHER

Oral stimulation tests

Intervention Type OTHER

Venous blood samples

Intervention Type OTHER

Samples for genetic studies (ancillary study)

Intervention Type OTHER

Healthy volunteers

Group Type OTHER

Measure the threshold of detection for linoleic acid

Intervention Type OTHER

Oral stimulation tests

Intervention Type OTHER

Venous blood samples

Intervention Type OTHER

Samples for genetic studies (ancillary study)

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Measure the threshold of detection for linoleic acid

Intervention Type OTHER

Oral stimulation tests

Intervention Type OTHER

Venous blood samples

Intervention Type OTHER

Samples for genetic studies (ancillary study)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* persons who have provided written consent
* Healthy volunteers:
* Men \> 18 years
* 19 \<BMI \< 25 kg.m-2
* Fasting triglyceridemia \< 1.50 g/l
* Fasting glycemia \< 1.10 g/l
* Without regular medical treatment
* Patients with type-2 diabetes:
* Men \>18 years
* type 2 diabetes (fasting glycemia \> 7 mmol/l at the diagnosis) treated with diet or diet + oral antidiabetics (metformin, and/or insulinsecretion agents \[hypoglycemic sulphonamides, or glinides\] and/or glitazones and/or acarbose)
* Stable oral antidiabetic treatment for 3 months
* Obese non-diabetic patients:
* Men \> 18 years
* BMI 30 kg.m-2
* Fasting glycemia \< 1.10 g/l
* HbA1c \< 6.0%
* Absence of treatment with hypoglycemic agents (including benfluorex)
* Absence of medical treatment for obesity
* Absence of a history of surgery for obesity (band, by-pass) or gastric stimulator (type Tantalus)

Exclusion Criteria

* Persons not covered by the national health insurance
* Smokers, or smoking cessation within the 3 months preceding inclusion
* Persons with eating disorders:
* Severe digestive disease (enteropathy with absorption disorders, inflammatory digestive disease)
* Pancreatic insufficiency
* History of pancreas surgery
* Type 1 diabetes
* Renal insufficiency
* Hepatic insufficiency
* Treatment with proton pump inhibitors, insulin, GLP-1 analogues, DPP-4 inhibitors
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier Universitaire Dijon

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU Dijon

Dijon, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Bruno VERGES

Role: CONTACT

3 80 29 34 53 ext. +33

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Isabelle ROBIN

Role: primary

3 80 29 33 32 ext. +33

References

Explore related publications, articles, or registry entries linked to this study.

Besnard P, Christensen JE, Bernard A, Simoneau-Robin I, Collet X, Verges B, Burcelin R. Identification of an oral microbiota signature associated with an impaired orosensory perception of lipids in insulin-resistant patients. Acta Diabetol. 2020 Dec;57(12):1445-1451. doi: 10.1007/s00592-020-01567-9. Epub 2020 Jul 16.

Reference Type DERIVED
PMID: 32676702 (View on PubMed)

Chevrot M, Passilly-Degrace P, Ancel D, Bernard A, Enderli G, Gomes M, Robin I, Issanchou S, Verges B, Nicklaus S, Besnard P. Obesity interferes with the orosensory detection of long-chain fatty acids in humans. Am J Clin Nutr. 2014 May;99(5):975-83. doi: 10.3945/ajcn.113.077198. Epub 2014 Feb 12.

Reference Type DERIVED
PMID: 24522446 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

VERGES 2009

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Glucose, Brain and Microbiota
NCT03889132 ACTIVE_NOT_RECRUITING
Postprandial VLDL-TG Metabolism
NCT01961024 COMPLETED
Postprandial Dysmetabolism
NCT00813215 UNKNOWN NA